Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. [electronic resource]
Producer: 20121217Description: R11 p. digitalISSN:- 1478-6362
- Adult
- Aged
- Aged, 80 and over
- Antirheumatic Agents -- adverse effects
- Area Under Curve
- Arthritis, Rheumatoid -- drug therapy
- CCR5 Receptor Antagonists
- Constipation -- chemically induced
- Cyclohexanes -- adverse effects
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Male
- Maraviroc
- Metabolic Clearance Rate
- Methotrexate -- adverse effects
- Middle Aged
- Nausea -- chemically induced
- Treatment Failure
- Triazoles -- adverse effects
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.